Company profile
Ticker
TCRX
Exchange
Website
CEO
Dr. Gavin MacBeath Ph.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
New Newscorp Inc, New Newscorp LLC
SEC CIK
Corporate docs
Subsidiaries
TScan Securities Corporation ...
IRS number
825282075
TCRX stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
26 Dec 24
424B5
Prospectus supplement for primary offering
26 Dec 24
8-K
Entry into a Material Definitive Agreement
23 Dec 24
8-K
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase
10 Dec 24
8-K
Unregistered Sales of Equity Securities
21 Nov 24
10-Q
2024 Q3
Quarterly report
12 Nov 24
8-K
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
12 Nov 24
8-K
Entry into a Material Definitive Agreement
1 Nov 24
10-Q
2024 Q2
Quarterly report
12 Aug 24
8-K
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
12 Aug 24
Latest ownership filings
SC 13G/A
K2 HealthVentures Equity Trust LLC
14 Feb 25
SC 13G/A
Lynx1 Capital Management LP
14 Feb 25
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
12 Feb 25
4
ZORAN ZDRAVESKI
11 Feb 25
4
Leiden Dworak
11 Feb 25
4
Gavin MacBeath
11 Feb 25
4
Jason Amello
11 Feb 25
4
Chrystal Louis
11 Feb 25
4
Weston Nichols
30 Dec 24
4
Weston Nichols
16 Dec 24
Financial summary
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q | |
Cash on hand (at last report) | 138.15 mm | 138.15 mm | 138.15 mm | 138.15 mm | 138.15 mm | 138.15 mm |
Cash burn (monthly) | 36.35 mm | 1.84 mm | 10.87 mm | 9.96 mm | 9.31 mm | 8.93 mm |
Cash used (since last report) | 170.23 mm | 8.62 mm | 50.93 mm | 46.63 mm | 43.58 mm | 41.83 mm |
Cash remaining | -32.08 mm | 129.53 mm | 87.22 mm | 91.52 mm | 94.57 mm | 96.32 mm |
Runway (months of cash) | -0.9 | 70.4 | 8.0 | 9.2 | 10.2 | 10.8 |
Institutional ownership, Q3 2024
13F holders | Current |
---|---|
Total holders | 95 |
Opened positions | 21 |
Closed positions | 13 |
Increased positions | 27 |
Reduced positions | 17 |
13F shares | Current |
---|---|
Total value | 207.66 bn |
Total shares | 57.91 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
K2 HealthVentures Equity Trust | 5.32 mm | $25.18 mm |
Lynx1 Capital Management | 5.22 mm | $26.02 bn |
Biotechnology Value Fund L P | 5.07 mm | $24.00 mm |
EcoR1 Capital | 5.00 mm | $24.90 bn |
BlackRock | 4.63 mm | $23.07 bn |
Adage Capital Partners GP, L.L.C. | 4.40 mm | $21.91 bn |
BVF | 2.99 mm | $14.89 bn |
Baker Bros. Advisors | 2.78 mm | $13.87 bn |
Vanguard | 2.35 mm | $11.69 bn |
Propel Bio Management | 2.09 mm | $10.39 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Jan 25 | Jason Amello | Stock Option Voting Common Stock | Grant | Acquire A | No | No | 3.065 | 270,000 | 827.55 k | 270,000 |
3 Jan 25 | Chrystal Louis | Stock Option Voting Common Stock | Grant | Acquire A | No | No | 3.065 | 400,000 | 1.23 mm | 400,000 |
26 Dec 24 | Lynx1 Capital Management | Pre-funded Warrant Common Stock | Buy | Acquire P | Yes | No | 4 | 7,500,000 | 30.00 mm | 7,500,000 |
13 Dec 24 | Lynx1 Capital Management | Common Stock | Buy | Acquire P | Yes | No | 2.9014 | 100,000 | 290.14 k | 5,357,347 |
12 Dec 24 | Lynx1 Capital Management | Common stock, $0.0001 par value per share ("Common Stock") | Buy | Acquire P | Yes | No | 3.0072 | 31,800 | 95.63 k | 5,257,347 |
15 Nov 24 | Lynx1 Capital Management | Common stock, $0.0001 par value per share | Buy | Acquire P | Yes | No | 4.3442 | 947 | 4.11 k | 5,225,547 |
News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
1mo ago
Why Is TScan Therapeutics Stock Gaining Today?
1mo ago
Market-Moving News for December 26th
1mo ago
The Analyst Landscape: 5 Takes On TScan Therapeutics
2mo ago
HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $15 Price Target
2mo ago
Press releases
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
1d ago
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
1mo ago
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
1mo ago
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
2mo ago
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
2mo ago